Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Investor Presentation (April 2022)
39 slides from Innate Pharma Sa Class A's investor presentation, Apr 15, 2022
Slide 1: Company Overview
Company Overview April 2022 PARIS: IPH.PA NASDAQ: IPHA © 2020 Innate Pharma. All rights reserved.
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: A Leading Company in the Field of Innate Immunity
A Leading Company in the Field of Innate Immunity • Global, clinical-stage oncology-focused MARSEILLE FRANCE biotech company. ROCKVILLE MARYLAND • Scientific excellence in the field of innate immunity with expertise in natural killer cell biology and antibody engineering. • Focused pipeline of antib
Slide 4: Scientific Innovation Drives Our Strategy
Scientific Innovation Drives Our Strategy We aim to harness our scientific know-how in innate immunity and antibody engineering to develop oncology products that improve the lives of patients Drive near-term Advance our Build a sustainable value with innovative R&D business through Lacutamab pipelin
Slide 5: Strong Science + Strong Partnerships = Robust Pipeline
Strong Science + Strong Partnerships = Robust Pipeline Validated Strong Track Robust Science Record of Pipeline in high-impact Collaborations with innovative publications pre-clinical and with industry and clinical assets academia 5
Slide 6: Innate's Approach: Harnessing Innate Immunity in Cancer
Innate’s Approach: Harnessing Innate Immunity in Cancer Choosing the right targets to leverage the body’s immune response Priming and activation (APCs and T cells) Engage NK cells 1 towards tumor Cancer antigen presentation (DCs) Lacutamab (KIR3DL2) Lymph node Trafficking of (NKp46) T cells to tumor
Slide 7: Our Robust Pipeline of Proprietary & Partnered Assets
Our Robust Pipeline of Proprietary & Partnered Assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Status Sézary Syndrome TELLOMAK PHASE 2 (FDA FAST TRACK/EMA PRIME DESIGNATION) Preliminary Phase 2 data expected 2022 Early data presented Mycosis Fungoides TELLOMAK PHASE 2 Prelimina
Slide 8: Driving Our Proprietary Portfolio
Driving Our Proprietary Portfolio
Slide 9: Lacutamab: Lead Proprietary Asset
LACUTAMAB Lacutamab: Lead Proprietary Asset First-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody lacutamab • Lacutamab under development for the treatment of various forms of T-cell lymphomas (TCL) KIR3DL2 • Compelling Phase 1 data in Sézary syndrome (SS), published in Lancet Oncolog
Slide 10: Development Informed by Target Expression
LACUTAMAB Development Informed by Target Expression KIR3DL2 EXPRESSION INCIDENCE Major markets (US, EU5, Japan), 2025 SEZARY SYNDROME • >90% of patients express target* ~80–200 patients1 • All tissues involved (skin, blood and lymph nodes) MYCOSIS FUNGOIDES 2,200–4,000 patients1 • ~50% of patients e
Slide 11: Developing New Standard of Care in KIR3DL2-Expressing T-Cell Lymphomas
LACUTAMAB Developing New Standard of Care in KIR3DL2-Expressing T-Cell Lymphomas Sezary Cutaneous Syndrome T-Cell Lymphoma Fast to market approach (CTCL) Niche indication with high unmet need Mycosis Fungoides Expand potential beyond SS Explore impact of KIR3DL2 expression on clinical outcome Periph
Slide 12: Compelling Phase 1 Results
LACUTAMAB Compelling Phase 1 Results FDA Fast Track Designation granted based on these results Sézary Syndrome Subgroup (n=35) Total 44 patients with CTCL ≥ 2 lines of therapy Best change in mSWAT as compared to baseline Best Global Response • 25 (incl. 20 SS) in dose escalation (intra-patient dose
Slide 13: TELLOMAK Phase 2 Study in Two CTCL Subtypes
LACUTAMAB TELLOMAK Phase 2 Study in Two CTCL Subtypes Potential for Sézary syndrome cohort to serve as pivotal trial Sézary Syndrome (N~60) Mycosis Fungoides (N~100) ≥ 2 prior systemic therapies ≥ 2 prior systemic therapies Cohort 1 Cohort 2# Cohort 3# All Comers* All comers, SS, must include KIR3DL
Slide 14: Encouraging Preliminary Results in KIR3DL2-Expressing MF Cohort of TELLOMAK Trial
LACUTAMAB Encouraging Preliminary Results in KIR3DL2-Expressing MF Cohort of TELLOMAK Trial Cohort 2 Overall response rate of ~35%* in advanced patient population with no current standard of care Cohort 3 Overall response rate of ~11%* KIR3DL2 non-expressors cohort did not progress to Stage 2 Cohort
Slide 15: Initiating Data-Driven Strategy in PTCL
LACUTAMAB Initiating Data-Driven Strategy in PTCL N O W N E X T S T E P S RELAPSED SETTING 03 FRONTLINE Highest unmet medical need; Driven by data in the relapsed two-pronged approach: setting to advance into earlier lines 02 • Monotherapy (Phase 1b study in H2 2021) • Combination with CHOP • Combin
Slide 16: Developing a New Standard of Care Across KIR3DL2-Expressing T-Cell Lymphomas
LACUTAMAB Developing a New Standard of Care Across KIR3DL2- Expressing T-Cell Lymphomas Cutaneous T-Cell Lymphoma (CTCL) Peripheral T-Cell Lymphoma (PTCL) Phase 2 TELLOMAK Trial Multi-trial Strategy Sezary Syndome Mycosis Fungoides From Relapsed to Frontline PTCL 80-200 patients 2,200-4,400 patients
Slide 17: Next-Generation Assets: NK Cell Engagers
Next-Generation Assets: NK Cell Engagers
Slide 18: NK Cells Offer Unique Cancer-Fighting Abilities
ANKETTM NK Cells Offer Unique Cancer-Fighting Abilities NK SPECIFICITY • NK cells are not expected to produce a cytokine storm NK cells in • NKp46 is the most specific activating receptor of NK cells periphery N K p 4 6 E X P R E S S I O N S TA B I L I T Y NKp46 • Unlike many other activating recept
Slide 19: ANKET: Innate's Proprietary NK Cell Engager Platform
ANKETTM ANKET™: Innate’s Proprietary NK Cell Engager Platform ANKET™ Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46 is a versatile, fit-for- purpose technology that is creating Provides proliferation and activation signals
Slide 20: New Data from IPH6101/SAR443579, Innate's Lead ANKET Asset
ANKETTM New Data from IPH6101/SAR443579, Innate’s Lead ANKET™ Asset Research collaboration with partner Sanofi; Phase 1/2 clinical trial underway First NKp46/CD16-based Uses Innate’s Announced €7M NK cell engager that proprietary multi-specific milestone payment to targets CD123 on AML antibody form
Slide 21: CD123 tri-specific SAR443579/IPH6101 Demonstrates Potent Antitumor Activity Against AML
ANKETTM CD123 tri-specific targeted SAR443579/IPH6101 Demonstrates Potent Antitumor Activity Against AML and Favorable Safety Profile SAR443579/IPH6101 kills AML cells resistant to ADCC SAR443579/IPH6101 induce CD123-expressing cell depletion in NHP with minor cytokine release ADCC-sensitive AML cel
Slide 22: Optimal Efficacy Requires All Arms in Tetra-specific ANKET
ANKETTM Optimal Efficacy Requires All Arms in Tetra-specific ANKET™ Demonstrate Superiority in Preclinical Model of Tumors Solid tumor models Disseminated tumor models Progressing towards IND enabling studies TAg: Tumor antigen *ADCC-enhanced mAb 22
Slide 23: Different Receptors have Different Effects on NK cells
ANKETTM Different Receptors have Different Effects on NK cells NKG2D NKp46 CD16 IL-2Rb IL-2Rg DAP10 CD3ζ, FcRγ # • NK cell activation + • NK cell activation +++ • Proliferation +++ • cytotoxicity • cytotoxicity • cytokines and chemokines Adapted from Lanier, Nature Immunol 2008; Vivier et al., Scien
Slide 24: Building a Sustainable Business
Building a Sustainable Business
Slide 25: Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams
MONALIZUMAB Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams Positive COAST randomized Phase 2 trial; AstraZeneca planning a second Phase 3 monalizumab trial based on results Promotes Anti-tumor Immunity by 2H21: COAST Trial Demonstrates Improved Clinical Unleashing B
Slide 26: Monalizumab: Early NSCLC
MONALIZUMAB Monalizumab: Early NSCLC Phase 3 program underway, sponsored by AstraZeneca, for patients with unresectable, Stage III NSCLC NSCLC Phase 3 in unresectable, Stage III NSCLC STAGE I STAGE II STAGE III STAGE IV Phase 2 NeoCOAST* Phase 2 COAST* Stg I-IIIA NSCLC Unresect. Stg III NSCLC monali
Slide 27: Monalizumab: NSCLC
Monalizumab : NSCLC 2021 and AACR 2022 data presentations provide rationale for further exploration in NSCLC NeoCOAST: open-label, randomized, phase 2, multidrug platform study of COAST Phase 2 study of durvalumab alone or in combination with novel agents in neoadjuvant durvalumab alone or combined
Slide 28: Monalizumab: Head and Neck cancer
MONALIZUMAB Monalizumab: Head and Neck cancer Innate’s first Phase 3 program, sponsored by AstraZeneca, for patients with IO-pretreated SCCHN SCCHN 2L+ Phase 3 trial underway R/M SCCHN 1L 2L+ Phase 2 Cohort 3 Phase 2 Cohort 2 1L R/M SCCHN Post PDx R/R SCCHN monalizumab + durvalumab + cetuximab monal
Slide 29: Catalysts and Summary
(fo) Catalysts and Summary &S innate pharma
Slide 30: Key Newsflow Over the Next 2 Years
Key Newsflow Over the Next 2 Years 2 0 2 2 Data Readouts Clinical Progress • Monalizumab NeoCOAST Ph2 NSCLC (AstraZeneca) AACR • Monalizumab PACIFIC-9 NSCLC Phase 3 start (AstraZeneca) • Lacutamab Phase 2 MF data (preliminary) H2 • Monalizumab NeoCOAST-2 Phase 2 start (AstraZeneca) • Lacutamab Phase
Slide 31: Early R&D focus to drive value through later stage partnerships
Early R&D focus to drive value through later stage partnerships Lacutamab R&D pipeline Partnerships • TELLOMAK read-out with MF in • Advancing proprietary tetra- • Strong Phase 3 monalizumab 2021 and preliminary data for MF specific NK cell-targeted platform collaboration with AstraZeneca and SS in
Slide 32: Thank You
THANK YOU www.innate-pharma.com PARIS: IPH.PA NASDAQ: IPHA © 2020 Innate Pharma. All rights reserved.
Slide 33: Appendix
Appendix & innate pharma
Slide 34: 2021 Financial Highlights
2021 Financial Highlights Cash, cash equivalents and financial assets: €159.7m* as of December 31, 2021 • Sufficient to fund operations until mid 2023 Revenue/other income from continuing Operating expenses from continuing operations**: operations** : €24.7m €72.5m Licensing and collaborations: €12.
Slide 35: Putting Lacutamab Phase 1 Data into Clinical Context
LACUTAMAB Putting Lacutamab Phase 1 Data into Clinical Context Recent results in MF/Sézary patients Mogamulizumab Vorinostat Patient population Patients who received at least one prior systemic therapy Response rate MF/SS: 28% MF/SS: 5% MF: 21% MF: 7% SS: 37% Sézary: 2% Median progression-free survi
Slide 36: Monalizumab R/M SCCHN: Updated Results from Phase 2 Trial
MONALIZUMAB Monalizumab R/M SCCHN: Updated Results from Phase 2 Trial Cohort 2 post platinum and post anti-PD-(L)1 (n=40) Best Change of Tumor Size From Baseline • Population with high medical need • R/M SCCHN post platinum and post anti-PD-(L)1 where no treatment options are currently approved glob
Slide 37: IPH5201 (Anti-CD39) and IPH5301 (Anti-CD73)
IPH5201 & IPH5301 IPH5201* (Anti-CD39) and IPH5301 (Anti-CD73) Targeting immunosuppressive tumor microenvironment • CD39 and CD73 are enzymes expressed on different cells in the TME • Promote immuno-suppression by degrading pro-inflammatory ATP into immunosuppressive adenosine • IPH5201: ongoing Pha
Slide 38: IPH5201: Preclinical Data
IPH5201 IPH5201*: Preclinical Data Significant tumor responses observed in response to treatment with PD-1 inhibitors and ADCC-inducing antibodies, as well as with immunogenic chemotherapy, compared to responses to these agents in wild-type mice Sources: Perrot et al., Cell Reports 2019 *2018 collab
Slide 39: IPH5301: Preclinical Data
IPH5301 IPH5301: Preclinical Data IPH5301 more potent in restoring CD4+ and CD8+ T-cell proliferation in an ATP-suppression assay, than the most advanced clinical candidates CD4+ T cells + CD8+ T+ cells C D 4 T c e lls C D 8 T c e lls c o n tr o l) * * * r a te 1 0 0 * * * * 1 0 0 * * * 8 0 8 0 P r